Skip to content
Acutaas Chemicals logo

Acutaas Chemicals

ACUTAAS NSE
₹3,777.30 −126.70 (−3.25%)
P/E
80.08
View as Markdown
MCP
Close 4 Nov 2026 ₹3,777.30 +2,007.40 +113% 1Y
Start ₹1,769.90

Key Fundamentals

SmallcapPharmaceuticals & BiotechnologyHealthcare

Price-based figures as of · EPS basis: Consolidated · TTM

ROCE
31.60%
Debt to Equity
0.02
EPS (TTM)
₹47.17
Book Value
₹226.87
Market Cap
—
P/E (TTM)
80.08
P/B
16.65
ROE
24.00%
Dividend Yield
0.06%
EBITDA
₹522 Cr
52W High
₹4,045.30
52W Low
₹1,570.00
Day Range
₹3,759.00 – ₹3,953.90
Volume
3,73,994

Peer Comparison

Healthcare › Pharmaceuticals

Acutaas Chemicals peer comparison
Sun Pharma
₹1,773.4038.81₹4,29,049 Cr4.770.90%16.00%20.50%₹61,631 Cr₹10,987 Cr
Divis Laboratories
₹10,037.5091.10₹2,65,269 Cr15.900.30%16.50%22.00%₹11,230 Cr₹2,925 Cr
Torrent Pharmaceuticals
₹4,738.5078.61₹1,77,061 Cr9.810.82%27.40%15.20%₹17,400 Cr₹2,099 Cr
Zydus Life Science
₹1,188.1026.44₹1,25,446 Cr4.370.08%21.20%21.10%₹28,592 Cr₹4,593 Cr
Laurus Labs
₹2,323.80114.81₹1,25,228 Cr20.720.04%18.30%17.80%₹7,270 Cr₹1,090 Cr
Dr Reddys Laboratories
₹1,374.0035.59₹1,14,543 Cr2.960.58%11.20%13.00%₹33,228 Cr₹3,184 Cr
Cipla
₹1,402.0033.59₹1,12,454 Cr3.200.93%11.60%15.50%₹28,324 Cr₹3,356 Cr
Acutaas Chemicals (this company)
₹3,777.3080.08₹31,154 Cr16.650.06%24.00%31.60%₹1,462 Cr₹387 Cr
Median 8 companies₹2,048.6058.71₹1,25,337 Cr7.290.44%17.40%19.15%₹22,862 Cr₹3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

52 Average

Data confidence 100/100

surveillance:ASM1

Category scores

Quality
52
Average
Returns, margins, earnings quality 22% weight
Valuation
20
Poor
Cheap vs sector & own history 24% weight
Growth
97
Strong
Sales & profit trajectory 9% weight
Financial Health
85
Strong
Solvency, leverage, coverage 9% weight
Momentum
75
Strong
Trend strength, vol-adjusted 12% weight
Ownership
56
Good
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

3
  • Company is almost debt free.
  • Company is expected to give good quarter
  • Company has delivered good profit growth of 45.8% CAGR over last 5 years

Weaknesses

2
  • Stock is trading at 15.9 times its book value
  • Promoter holding has decreased over last 3 years: -6.27%

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bullish1513
OscillatorsBullish153
Moving AveragesStrong Bullish0010

Key readings

RSI (14)
61.47
Neutral
MACD (12,26,9)
176.43
Bullish
SMA (50)
3,322.23
Bullish
SMA (200)
2,851.24
Bullish

As of

Analyst Rating

Based on 8 analysts
BUY75%

6 of 8 analysts rate Buy, 0 Hold, 2 Sell.

As of

BUY
6
75%
HOLD
0
0%
SELL
2
25%

Growth Rate

From the financial statements below. 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
5Y+31.46%
3Y+29.47%
1Y+32.97%
TTM+40.98%

Net profit

Net profit growth by window
5Y+45.82%
3Y+62.48%
1Y+122.50%
TTM+103.68%

Operating cash flow

Operating cash flow growth by window
5Y+59.83%
3Y+64.16%
1Y+147.46%
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
5Y+12.39 pp
3Y+15.91 pp
1Y+12.81 pp
TTM+12.65 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2017₹160 Cr
Mar 2018₹188 Cr
Mar 2019₹239 Cr
Mar 2020₹240 Cr
Mar 2021₹341 Cr
Mar 2022₹520 Cr
Mar 2023₹617 Cr
Mar 2024₹717 Cr
Mar 2025₹1,007 Cr
Mar 2026₹1,339 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2017₹12.00 Cr
Mar 2018₹18.00 Cr
Mar 2019₹23.00 Cr
Mar 2020₹27.00 Cr
Mar 2021₹54.00 Cr
Mar 2022₹72.00 Cr
Mar 2023₹83.00 Cr
Mar 2024₹49.00 Cr
Mar 2025₹160 Cr
Mar 2026₹356 Cr

Analyst Forecasts

Forecast For
Dec 26 consensus · EBITDA
₹200 Cr +10.3% vs Sep 26
Reported High Mean Low

AI Analysis — Bull vs Bear

Figures as of 2 Nov 2026
AI opinion · based on fundamentals
Risk high

Acutaas Chemicals Ltd trades at ₹3,892.6 as of 2026-11-02 with a market cap of ₹32,764 crore, commanding a P/E of 82.52x and P/B of 17.16x. The company has delivered exceptional profit growth of 104% TTM and 62% compounded over three years, underpinned by a near debt-free balance sheet (debt-to-equity of 0.02), though the stock's steep valuation multiples and declining promoter holding warrant careful scrutiny.

Bull Case 8
  • TTM profit growth stands at 104%, indicating a sharp acceleration in earnings momentum
  • Company is virtually debt-free with a debt-to-equity ratio of just 0.02, providing significant financial flexibility and low interest burden
  • ROCE of 27.72% reflects highly efficient capital deployment and strong operational economics
  • Compounded profit growth of 62% over three years and 46% over five years demonstrates sustained long-term earnings expansion
  • ROE of 20.83% as of the latest period, with the last-year figure reaching 24%, signals improving return generation for shareholders
  • Compounded sales growth of 30% over three years and 32% over five years shows consistent top-line traction alongside profit growth
  • Stock has rallied from a 52-week low of ₹1,570 to ₹3,892.6, a gain of roughly 148%, reflecting strong market confidence in the business trajectory
  • TTM sales growth of 41% suggests the revenue acceleration is ongoing and not merely a base-effect recovery
Bear Case 5
  • P/E of 82.52x is significantly elevated, requiring sustained high-growth execution to justify current valuation levels
  • Promoter holding has declined by 6.27% over the last three years, which may signal reduced insider conviction or dilution
  • Dividend yield of just 0.06% means shareholders are almost entirely dependent on capital appreciation for returns
  • Three-year and five-year average ROE of 18% is notably lower than the last-year figure of 24%, raising questions about whether the recent improvement is sustainable or cyclical
  • At a market cap of ₹32,764 crore, any deceleration in the 62% three-year profit CAGR could lead to a sharp de-rating of the premium multiple

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

9h ago

TL;DR: Acutaas Chemicals is firing on most cylinders with Q2 revenue up 42.8%, PAT up 71.4%, and margin expansion driving a record stock price of ₹3,900. The upward revision of FY27 guidance to ~30% revenue growth and 38-40% EBITDA margins signals management confidence, bolstered by the early South Korea facility launch and Enchem acquisition. Key risks include softness in the specialty chemicals segment and BFC business disruption from a US client ownership change. The trend is strongly improving, though sustaining 40%+ margins and diversifying beyond pharma intermediates will be critical to maintaining momentum.

Headwinds 2
  • BFC business hit by client change Oct 27

    The BFC business was impacted during Q2 due to a change in ownership of the US customer, creating near-term revenue uncertainty in that segment.

  • Specialty chemicals segment subdued Oct 27

    The specialty chemicals business remained soft during the September quarter, partially offsetting strong growth in pharma intermediates and CDMO.

Positives 6
  • Q2 revenue up 42.8% YoY Oct 27

    September quarter revenue rose 42.8% YoY to ₹437 crore, PAT jumped 71.4% to ₹123.1 crore, and EBITDA surged 86.3% to ₹177 crore with margin expanding to 40.5%.

  • FY27 guidance revised upward Oct 27

    Revenue growth guidance raised from 25% to ~30% for FY27, with EBITDA margin guidance lifted to the 38-40% range citing improved visibility and a robust order pipeline.

  • Stock hits record ₹3,900 Oct 27

    Shares surged 13% to a record ₹3,900 intraday, up 119% over 12 months and 580% over five years, making it a standout multibagger.

Neutral 1
  • Senior management restructuring Nov 2

    Dr. Ashish Kumar Pandey appointed AVP and SMP effective November 2, 2026, bringing 30+ years of experience. Mr. Shukla and Mr. Desai lost SMP designation due to reporting changes but continue heading Units 2 and 3.

Quarterly Results

₹ Cr
ACUTAAS quarterly results, ₹ crore
Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales
154
172
166
225
177
247
275
308
207
306
393
433
330
437
Expenses
120
148
140
182
147
198
206
224
156
211
243
249
217
261
Operating Profit
34
25
27
43
30
49
69
85
51
95
151
184
113
176
OPM %
22%
14%
16%
19%
17%
20%
25%
28%
25%
31%
38%
42%
34%
40%
Other Income
1
−30
3
1
1
8
2
6
16
10
5
11
2
5
Interest
1
1
3
2
4
0
1
1
1
1
1
1
1
1
Depreciation
3.42
4
4
5
6
7
6
7
8
8
10
10
10
13
PBT
31
−10
24
37
20
50
63
83
58
96
145
184
104
167
Tax %
28%
71%
25%
31%
26%
25%
28%
24%
24%
25%
27%
27%
28%
26%
Net Profit
22
−17
18
26
15
38
45
63
44
72
106
134
75
123
EPS (₹)
2.71
−2.55
2.27
3.41
1.71
4.56
5.49
7.63
5.41
8.82
13.19
16.09
9.07
—

Sep 2026: from the results filed on 27 Oct 2026, ahead of the full statement, so some rows are blank.

Profit & Loss

₹ Cr
ACUTAAS profit and loss, annual, ₹ crore
Particulars Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
160
188
239
240
341
520
617
717
1,007
1,339
1,462
Expenses
137
157
196
198
260
415
493
589
775
859
919
Operating Profit
23
31
42
42
80
105
123
128
232
480
543
OPM %
14%
16%
18%
17%
24%
20%
20%
18%
23%
36%
37%
Other Income
0
3
0
2
1
3
4
−25
17
42
27
Interest
3
3
5
6
6
6
2
6
6
3
4
Depreciation
1
2
3
4
4
10
12
16
27
36
38
PBT
19
28
35
35
72
91
112
82
216
483
529
Tax %
35%
35%
34%
21%
25%
21%
26%
41%
26%
26%
—
Net Profit
12
18
23
27
54
72
83
49
160
356
387
EPS (₹)
1.91
2.94
3.7
4.36
8.57
9.87
11.43
5.8
19.38
43.51
47.17
Div. Payout %
0%
0%
0%
0%
0%
15%
13%
26%
8%
6%
—

Balance Sheet

₹ Cr
ACUTAAS balance sheet, annual, ₹ crore
Particulars Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
2
2
10
10
32
36
36
37
41
41
Reserves
37
56
72
101
135
486
558
637
1,269
1,613
Borrowings
27
44
54
59
137
1
4
217
13
36
Other Liabilities
43
54
77
61
110
136
169
205
227
295
Total Liabilities
109
155
213
232
413
659
767
1,096
1,549
1,984
Fixed Assets
28
32
79
85
186
205
259
427
570
745
CWIP
11
30
2
12
0
3
30
125
130
332
Investments
1
3
2
2
1
2
2
0
0
0
Other Assets
68
91
131
133
225
450
477
543
848
907
Total Assets
109
155
213
232
413
659
767
1,096
1,549
1,984

Cash Flow

₹ Cr
ACUTAAS cash flow, annual, ₹ crore
Particulars Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
29
8
15
27
28
−12
66
125
118
292
Investing
−19
−25
−21
−24
−101
−121
−33
−365
−224
−266
Financing
−7
15
6
0
72
140
−12
239
261
4
Net Cash Flow
3
−2
0
3
−1
8
20
−1
156
30
Free Cash Flow
10
−16
−7
6
−77
−46
−31
−155
−76
−36
CFO/EBITDA
153
53
68
85
52
10
73
116
71
84

Ratios

ACUTAAS financial ratios, annual
Particulars Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
83
97
116
86
129
115
136
105
105
99
Inventory Days
76
89
95
148
123
150
131
139
119
149
Days Payable
148
154
168
146
172
158
157
119
103
99
Cash Conversion Cycle
11
31
43
88
80
107
111
125
121
149
Working Capital Days
46
64
28
34
51
141
139
80
123
116
ROCE %
—
38%
34%
27%
33%
24%
21%
16%
20%
32%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Acutaas Chemicals insights

74 extracted metrics across FY17–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 32.66%
  • FIIs 22.62%
  • Public 21.15%
  • DIIs 19.40%
  • Others 4.16%
  • Government 0.01%

No promoter shares pledged as of 14 Oct 2026

Change vs previous quarter

Not shown for some quarters: Others. Not available separately for this quarter: the shareholding filing gives Public and Others as one figure, shown under Public, so Others is left blank rather than estimated.

Documents

Frequently Asked Questions about Acutaas Chemicals

What does Acutaas Chemicals Ltd do?
Ami Organics Limited is one of the leading research and development-driven manufacturers of specialty chemicals. The company manufactures different types of Advanced Pharmaceutical Intermediates and Active Pharmaceutical Ingredients (API) for New Chemical Entities, and materials for agrochemicals…
Where is Acutaas Chemicals Ltd (ACUTAAS) listed?
Acutaas Chemicals Ltd trades as ACUTAAS on the NSE and under code 543349 on the BSE.
Which sector does Acutaas Chemicals Ltd belong to?
Acutaas Chemicals Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the PE ratio of Acutaas Chemicals Ltd?
Acutaas Chemicals Ltd trades at a PE ratio of 80.08 as of 4 Nov 2026, on earnings per share of ₹47.17, against a book value of ₹226.87 per share.
What is the 52-week high and low of Acutaas Chemicals Ltd?
Over the last 52 weeks Acutaas Chemicals Ltd has traded between ₹1,570 and ₹4,045.3 as of 4 Nov 2026.
Does Acutaas Chemicals Ltd pay dividends?
Acutaas Chemicals Ltd has a dividend yield of 0.06%.
What is the Return on Equity (ROE) of Acutaas Chemicals Ltd?
Acutaas Chemicals Ltd reported a return on equity of 24.00%. Its debt-to-equity ratio is 0.02.

Company Information

Ami Organics Limited is one of the leading research and development-driven manufacturers of specialty chemicals. The company manufactures different types of Advanced Pharmaceutical Intermediates and Active Pharmaceutical Ingredients (API) for New Chemical Entities, and materials for agrochemicals and fine chemicals.

Website amiorganics.com
CEO Mr. Nareshkumar Ramjibhai Patel
Employees 879
Listed 14 Sep 2021
Face Value ₹5

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/ACUTAAS.md for Acutaas Chemicals Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month